Last reviewed · How we verify
Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer
Approved treatments
- Alunbrig · Takeda
Alunbrig works by blocking the activity of the ALK tyrosine kinase receptor, which is involved in the growth and spread of cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer patent landscape — cliff calendar, originator estates, attackable patents
- Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer treatment landscape brief
- Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer treatment updates RSS
Frequently asked questions about Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer
What drugs treat Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer?
Tracked treatments include Alunbrig.
What is the treatment for Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer?
Standard treatment for Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer includes Alunbrig. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer patent cliff · Advanced/recurrent anaplasticlymphoma kinase (ALK)-positive non-small cell lung cancer CI report
- Treatment: Alunbrig · Takeda
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing